222 related articles for article (PubMed ID: 15197798)
1. Does pT2b prostate carcinoma exist? Critical appraisal of the 2002 TNM classification of prostate carcinoma.
Eichelberger LE; Cheng L
Cancer; 2004 Jun; 100(12):2573-6. PubMed ID: 15197798
[TBL] [Abstract][Full Text] [Related]
2. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer pathologic stage pT2b (2002 TNM staging system): does it exist?
Quintal MM; Magna LA; Guimaraes MS; Ruano T; Ferreira U; Billis A
Int Braz J Urol; 2006; 32(1):43-7. PubMed ID: 16519827
[TBL] [Abstract][Full Text] [Related]
4. Pathologic staging of prostate carcinoma. What are the issues?
Grignon DJ; Sakr WA
Cancer; 1996 Jul; 78(2):337-40. PubMed ID: 8674013
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer.
Hong SK; Han BK; Chung JS; Park DS; Jeong SJ; Byun SS; Choe G; Lee SE
BJU Int; 2008 Nov; 102(9):1092-6. PubMed ID: 18671786
[TBL] [Abstract][Full Text] [Related]
6. Ability of the 1992 and 1997 American Joint Committee on Cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease.
Han M; Walsh PC; Partin AW; Rodriguez R
J Urol; 2000 Jul; 164(1):89-92. PubMed ID: 10840430
[TBL] [Abstract][Full Text] [Related]
7. [The 1992 TNM classification of T2 prostate cancer predicts pathologic stage and prognosis better than the revised 1997 classification].
Koh H; Maru N; Muramoto M; Wheeler TM; Scardino PT; Ohori M
Nihon Hinyokika Gakkai Zasshi; 2002 Jul; 93(5):595-601. PubMed ID: 12174634
[TBL] [Abstract][Full Text] [Related]
8. Comparative assessment of the 1992 and 2002 pathologic T3 substages for the prediction of biochemical recurrence after radical prostatectomy.
Steuber T; Erbersdobler A; Graefen M; Haese A; Huland H; Karakiewicz PI
Cancer; 2006 Feb; 106(4):775-82. PubMed ID: 16400637
[TBL] [Abstract][Full Text] [Related]
9. Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer.
Ramos CG; Roehl KA; Antenor JA; Humphrey PA; Catalona WJ
J Urol; 2004 Jul; 172(1):137-40. PubMed ID: 15201754
[TBL] [Abstract][Full Text] [Related]
10. Staging of prostate cancer.
Cheng L; Montironi R; Bostwick DG; Lopez-Beltran A; Berney DM
Histopathology; 2012 Jan; 60(1):87-117. PubMed ID: 22212080
[TBL] [Abstract][Full Text] [Related]
11. Bladder neck invasion is an independent predictor of prostate-specific antigen recurrence.
Poulos CK; Koch MO; Eble JN; Daggy JK; Cheng L
Cancer; 2004 Oct; 101(7):1563-8. PubMed ID: 15378493
[TBL] [Abstract][Full Text] [Related]
12. Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score?
Roach M; Weinberg V; Sandler H; Thompson I
Cancer; 2007 Jan; 109(2):213-20. PubMed ID: 17167758
[TBL] [Abstract][Full Text] [Related]
13. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy.
Polascik TJ; Mayes JM; Sun L; Madden JF; Moul JW; Mouraviev V
Prostate; 2008 Sep; 68(13):1380-6. PubMed ID: 18543281
[TBL] [Abstract][Full Text] [Related]
14. Inadequacies of the current American Joint Committee on cancer staging system for prostate cancer.
Taylor SH; Merriman KW; Spiess PE; Pisters L
Cancer; 2006 Feb; 106(3):559-65. PubMed ID: 16369982
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value and clinical relevance of the 6th Edition 2002 American Joint Committee on Cancer staging system in patients with resectable hepatocellular carcinoma.
Lei HJ; Chau GY; Lui WY; Tsay SH; King KL; Loong CC; Wu CW
J Am Coll Surg; 2006 Oct; 203(4):426-35. PubMed ID: 17000385
[TBL] [Abstract][Full Text] [Related]
16. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database.
Scales CD; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL; Freedland SJ;
J Urol; 2007 Oct; 178(4 Pt 1):1249-52. PubMed ID: 17698131
[TBL] [Abstract][Full Text] [Related]
17. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy.
Kordan Y; Chang SS; Salem S; Cookson MS; Clark PE; Davis R; Herrell SD; Baumgartner R; Phillips S; Smith JA; Barocas DA
J Urol; 2009 Nov; 182(5):2291-5. PubMed ID: 19758638
[TBL] [Abstract][Full Text] [Related]
18. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer.
Boudreaux KJ; Clark PE; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Chang SS
J Urol; 2009 Feb; 181(2):540-5; discussion 546. PubMed ID: 19084855
[TBL] [Abstract][Full Text] [Related]
19. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
[TBL] [Abstract][Full Text] [Related]
20. A novel subclassification of pT2 gastric cancers according to the depth of muscularis propria invasion: superficial muscularis propria versus deep muscularis propria/subserosa.
Sun Z; Zhu GL; Lu C; Guo PT; Huang BJ; Li K; Xu Y; Wang ZN; Xu HM
Ann Surg; 2009 May; 249(5):768-75. PubMed ID: 19387327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
